Alerts will be sent to your verified email
Verify Email
PPLPHARMA
|
Piramal Pharma
|
Suven Pharma
|
Hikal
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
Domestic Sales Growth - YoY
|
15.43 % | n/a | n/a |
|
R&D as a % of Total Sales
|
0.71 % | 1.57 % | 4.01 % |
|
Financials
|
|||
|
5 yr Average ROE
|
4.5 % | 27.26 % | 10.48 % |
|
5yr average Equity Multiplier
|
1.97 | 1.3 | 2.17 |
|
5yr Average Asset Turnover Ratio
|
0.53 | 0.61 | 0.81 |
|
5yr Avg Net Profit Margin
|
4.14 % | 33.51 % | 5.87 % |
|
Price to Book
|
3.69 | 15.5 | 4.27 |
|
P/E
|
749.27 | 109.85 | 68.88 |
|
5yr Avg Cash Conversion Cycle
|
-17.8 Days | 70.98 Days | 33.87 Days |
|
Inventory Days
|
68.38 Days | 76.62 Days | 64.21 Days |
|
Days Receivable
|
76.2 Days | 42.46 Days | 101.46 Days |
|
Days Payable
|
156.5 Days | 85.69 Days | 96.57 Days |
|
5yr Average Interest Coverage Ratio
|
3.08 | 47.81 | 4.8 |
|
5yr Avg ROCE
|
6.74 % | 32.61 % | 13.73 % |
|
5yr Avg Operating Profit Margin
|
15.07 % | 43.1 % | 16.42 % |
|
5 yr average Debt to Equity
|
0.63 | 0.09 | 0.68 |
|
5yr CAGR Net Profit
|
-53.67 % | -1.08 % | -3.79 % |
|
5yr Average Return on Assets
|
2.39 % | 20.57 % | 4.82 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
34.95 % | 50.1 % | 68.85 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.16 % | -9.9 % | 0.08 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
12.19 % | 7.13 % | 2.17 % |
|
Piramal Pharma
|
Suven Pharma
|
Hikal
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Services Break-Up
|
Services Break-Up
|
-
|
-
|